Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Peflutren Lipid Microsphere Injectable Suspension
Peflutren Lipid Microsphere Injectable · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Peflutren Lipid Microsphere Injectable Suspension | DRUG | - |
Inclusion Criteria: * Diagnosed with 1 but \<7 focal liver lesions * Scheduled for liver biopsy within 30 days of study * Scheduled for CT or MR within 30 days of study Exclusion Criteria: * Critically ill subjects * Subjects with right-to-left shunts
Peflutren Lipid Microsphere Injectable is an investigational small molecule developed by Lantheus Holdings, Inc. (LNTH) for liver disease. It is formulated as a lipid microsphere injectable suspension and was studied in a Phase 2 trial assessing focal liver lesions. It is not approved and remains in clinical development.
Peflutren Lipid Microsphere Injectable is being developed for liver disease, specifically for the assessment of focal liver lesions. Its only recorded clinical trial enrolled patients with liver disease in the United Kingdom. The drug is investigational and has not been approved for any indication.
Peflutren Lipid Microsphere Injectable is developed by Lantheus Holdings, Inc., which trades on the Nasdaq under the ticker LNTH. Lantheus is the sponsor of the Phase 2 study of the agent in focal liver lesions.
Peflutren Lipid Microsphere Injectable is in Phase 2 development. One Phase 2 trial has been completed, and no trials are currently active. The drug is investigational and has not received FDA approval.
Peflutren Lipid Microsphere Injectable has been studied in one completed Phase 2 trial, NCT00162058, titled A Phase II Study of DMP 115 to Assess Focal Liver Lesions. The trial enrolled 80 patients with liver disease in the United Kingdom and was uncontrolled, with no randomization or blinding.
Yes. Peflutren Lipid Microsphere Injectable Suspension is an alternative name for Peflutren Lipid Microsphere Injectable. Both refer to the same Lantheus Holdings (LNTH) investigational small molecule being studied in liver disease.